Drug treatment of airway inflammation in asthma

Pharmacotherapy

Volumn 21, Issue 3 II, 2001, Pages

  Blake, K V ^a  

^a NEMOURS CHILDREN S CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CD4 IMMUNOGLOBULIN; CROMOGLYCATE DISODIUM; HISTAMINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; METHACHOLINE; MONOCLONAL ANTIBODY; NEDOCROMIL; PHOSPHODIESTERASE INHIBITOR; THEOPHYLLINE;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CONFERENCE PAPER; DRUG EFFICACY; DRUG RESEARCH; HUMAN; IMMUNOTHERAPY; LUNG LAVAGE; RESPIRATORY TRACT INFLAMMATION;

EID: 0035098458     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.4.3s.34265     Document Type: Conference Paper

References (95)

1. Bronchial responsiveness to histamine or methacholine in asthma: Measurement and clinical significance
2. The origin of airway hyperresponsiveness
3. Guidelines for methacholine and exercise challenge testing - 1999
4. A method for comparing the peak intensity and duration of action of aerosolized bronchodilators using bronchoprovocation with methacholine
5. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma
6. How do we monitor asthma control?
7. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment
8. Use of allergen bronchoprovocation to screen drugs for anti-asthma activity
9. Allergen-induced increase in bronchial responsiveness to histamine: Relationship to the late asthmatic response and change in airway caliber
10. Peripheral blood markers: Evaluation of inflammation in asthma
11. The use of induced sputum to investigate airway inflammation
12. Sputum induction to assess airway inflammation: Is it an inflammatory stimulus?
13. Bronchoalveolar lavage: Performance, sampling procedure, processing and assessment
14. Methods for sputum induction and analysis of induced sputum: A method for assessing airway inflammation in asthma
15. Biopsies: Bronchoscopic technique and sampling
16. Exhaled nitric oxide: A new lung function test
17. Exhaled nitric oxide as a marker in asthma
18. Nitric oxide in asthma. Pathogenic, therapeutic, or diagnostic?
19. Nitric oxide and airway disease
20. The biology of nitrogen oxides in the airways
21. Increased nitric oxide in exhaled air of asthmatic patients
22. Corticosteroids decrease exhaled nitric oxide in children with acute asthma
23. Expired nitric oxide levels during treatment of acute asthma
24. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients
25. Changes in the dose of inhaled steroid affect exhaled nitric oxide levels in asthmatic patients
26. Comparison of exhaled nitric oxide to spirometry during emergency treatment of asthma exacerbations with glucocorticoids in children
27. Inducible nitric oxide synthase in asthmatic airway epithelium is reduced by corticosteroid therapy
28. Endogenous nitric oxide in allergic airway disease
29. Orally exhaled nitric oxide levels are related to the degree of blood eosinophilia in atopic children with mild-intermittent asthma
30. Exhaled nitric oxide and sputum eosinophil markers of inflammation in asthmatic children
31. NO in exhaled air is correlated with markers of eosinophilic airway inflammation in corticosteroid-dependent childhood asthma
32. Changes in sputum eosinophils predict loss of asthma control
33. Non-invasive markers of airway inflammation as predictors of oral steroid responsiveness in asthma
34. Dissociation between exhaled nitric oxide and hyperresponsiveness in children with mild intermittent asthma
35. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma
36. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in mild to moderately severe asthma
37. Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma
38. Assessment of airway inflammation: An overview
39. Recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children-1999
40. Exhaled nitric oxide measurements in childhood asthma: Techniques and interpretation
41. Cromolyn sodium or nedocromil in childhood asthma: Does it matter?
42. The effect of inhaled sodium cromoglycate on cellular infiltration into the bronchial mucosa and the expression of adhesion molecules in asthmatics
43. A comparative study of the effects of ketotifen, disodium cromoglycate, and beclomethasone dipropionate on bronchial mucosa and asthma symptoms in patients with atopic asthma
44. Alternative agents for anti-inflammatory treatment of asthma
45. Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine
46. A comparison of the effects of sodium cromoglycate and beclomethasone dipropionate on pulmonary function and bronchial hyperreactivity in subjects with asthma
47. Long-term effect of cromolyn sodium on nonspecific bronchial hyperresponsiveness: A review
48. Theophylline attenuation of airway responses to allergen: Comparison with cromolyn metered-dose inhaler
49. Theophylline - An immunomodulatory role in asthma?
50. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma
51. Low-dose theophylline modulates T-lymphocyte activation in allergen-challenged asthmatics
52. Theophylline
53. Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy
54. The effects of theophylline on mucosal inflammation in asthmatic airways: Biopsy results
55. Effects of theophylline on inflammatory cells and cytokines in asthmatic subjects: A placebo-controlled parallel group study
56. Airways inflammation in nocturnal asthma
57. Theophylline: Potential antiinfiammatory effects in nocturnal asthma
58. Effects of theophylline on inhaled methacholine and histamine in asthmatic children
59. Theophylline has a dose-related effect on the airway response to inhaled histamine and methacholine in asthmatics
60. Relationship of different serum levels of theophylline on methacholine sensitivity
61. Theophylline inhibits early and late asthmatic reactions induced by allergens in asthmatic subjects
62. Theophylline does not inhibit allergen-induced increase in airway responsiveness to methacholine
63. Phosphodiesterase inhibitors: New opportunities for the treatment of asthma
64. Selective phosphodiesterase inhibitors for the treatment of bronchial asthma and chronic obstructive pulmonary disease
65. Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents
66. Phosphodiesterase 4 inhibitors and the treatment of asthma: Where are we now and where do we go from here?
67. Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients
68. The role of phosphodiesterase enzymes in allergy and asthma
69. The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects
70. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: From concept to clinic
71. Injection of anti-IgE antibodies will suppress IgE and allergic symptoms
72. Effects of anti-IgE in asthmatic subjects
73. IgE inhibition as a therapy for allergic disease
74. Treating asthma with anti-IgE or anti-IL5
75. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects
76. Treatment of allergic asthma with monoclonal anti-IgE antibody
77. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response
78. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects
79. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial
80. Soluble interleukin-4 receptor (sIL-4R) in allergic diseases
81. Effect of inhaled interleukin-4 on airway hyperreactivity in asthmatics
82. Interleukin-4 is required for the induction of lung Th2 mucosal immunity
83. Phase I/II study of recombinant interleukin-4 receptor (IL-4R) in adult patients with moderate asthma
84. A humanized anti-IL-5 monoclonal antibody, initial single dose safety and activity in patients with asthma
85. Anti-T cell strategies in asthma
86. CD4 T lymphocyte activation in acute severe asthma
87. CD4 T-lymphocyte activation in acute severe asthma. Relationship to disease severity and atopic status
88. CD4 T-lymphocyte activation is associated with peak expiratory flow variability in childhood asthma
89. CD4 T-lymphocyte activation in asthma is accompanied by increased serum concentrations of interleukin-5. Effect of glucocorticoid therapy
90. Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma
91. Cellular adhesion and interactions
92. Adhesion molecule strategies
93. The role of adhesion molecules in allergic inflammation and their suitability as targets of antiallergic therapy